IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

• Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored trial of INB-100 at the 65^th American Society of Hematology (ASH) Annual Meeting & Exposition
  
• Presented new data at Society for Neuro-Oncology (SNO) 28^th Annual Meeting highlighting the potential of INB-200 and INB-400 to treat patients with newly diagnosed glioblastoma multiforme (GBM), with all patients treated with mandated doses of INB-200 exceeding a progression-free survival of seven months
  
• Appointed internationally recognized immuno-oncology expert Dr. Corinne Epperly, M.D., M.P.H., to IN8bio’s Board of Directors
  
• Closed private placement in December 2023 with initial gross proceeds of $14.4 million giving a current cash runway into 2025 with potential total of $46.9 million in capital at increasing valuations
  

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent business updates and provided pipeline goals for 2024.

“2023 was a year marked by strong execution for IN8bio. We delivered on several clinical milestones, reporting positive data updates across our pipeline of innovative gamma-delta T cell therapies at many prestigious medical meetings, and secured the financing to extend our runway into 2025,” said William Ho, CEO and co-founder of IN8bio. “We continue to be excited by the data from the Phase 1 trial of INB-100, which showed that all evaluable patients remained in durable complete remission, with six patients remaining relapse free beyond one year. Importantly, we are excited that we are seeing in vivo expansion and persistence of allogeneic gamma-delta T cells, now out to 365 days. This persistence clearly differentiates our results from the data presented on other allogeneic cellular therapies to date and we believe this data underscores the far-reaching potential of gamma-delta T cells to help provide durable relapse-free periods in patients with hematologic malignancies undergoing haploidentical stem cell transplantation. We believe we are well positioned to execute on our clinical programs and are poised for many exciting updates in 2024.”